In a 3-year cohort study of adult patients with proven or probable IA, fewer patients initially treated with isavuconazole experienced adverse events compared with voriconazole, but more patients required a change in therapy due to lack of clinical efficacy.
Bibliographical noteFunding Information:
MPC receives salary support from a postdoctoral training grant, provided by the Fonds de recherche Santé Québec.
These results were presented in abstract form at IDWeek 2018, Abstract #358. This manuscript was prepared as part of routine work. MPC, JLO, EAH, TDB, IHS, KCC, AP, AEK, KC and SK have no relevant disclosures to report. FMM has received research grant support from Ansun, Astellas, Cidara, Chimerix, F2G, Gilead, Merck, Shire and WHISCON and has received consulting honoraria from Alexion, Amplyx, Astellas, Basilea, Fate, GlaxoSmithKline, Merck, Pfizer, Roche Molecular diagnostics, Shire and United Medical. SPH has research funding from Merck and AiCuris.
- invasive aspergillosis
PubMed: MeSH publication types
- Journal Article